Loading the company…
Loading the company…
㈜명문바이오
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 2018. Industry: Bio & Pharma. Revenue for 2025 was ₩32.8bn. It has 27 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2018-02-27 · latest registration 2023-10-25 · newest first
본 발명은 아트로핀의 제조방법에 관한 것이다. 보다 구체적으로, 조 아트로핀 황산염 일수화물에 잔류하는 불순물을 활성탄을 사용하여 효율적으로 제거하고, 산-염기 반응에 의해 황산염을 이탈시켜 아트로핀을 제조 및 결정화함으로써 순도가 높은 아트로핀을 얻을 수 있는 아트로핀의 제조방법에 관한 것이다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 1 of 1 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 40.2 | 32.8 |
| Cost of sales | 24.0 | 27.4 |
| Gross profit (loss) | 16.3 | 5.4 |
| Selling, general and administrative expenses | 19.1 | 7.4 |
| Operating income (loss) | (2.8) | (2.0) |
| Non-operating income | 0.2 | 0.2 |
| Other gains | 0.0 | 0.0 |
| Finance income | 0.0 | 0.0 |
| Other | 0.2 | 0.2 |
| Non-operating expenses | 0.5 | 0.1 |
| Other losses | 0.0 | — |
| Finance costs | 0.1 | 0.1 |
| Other | 0.4 | — |
| Profit (loss) before tax | (3.0) | (1.9) |
| Net income (loss) | (3.0) | (1.9) |
Revenue ₩32.8bn, down 18.4% YoY.
Operating margin -6.1% (prior -6.9%).
Net income ₩-1.9bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06